Anti-lysyl oxidase combined with a vacuum device induces penile lengthening by remodeling the tunica albuginea.
Amino Acids
/ metabolism
Aminopropionitrile
/ analogs & derivatives
Animals
Arterial Pressure
Collagen
/ metabolism
Combined Modality Therapy
Desmosine
/ metabolism
Elastin
/ metabolism
Enzyme Inhibitors
/ therapeutic use
Hydroxyproline
/ metabolism
Male
Organ Size
/ drug effects
Penile Erection
Penis
/ anatomy & histology
Protein-Lysine 6-Oxidase
/ antagonists & inhibitors
Rats
Rats, Sprague-Dawley
Vacuum
anti-lysyl oxidase
crosslinking
penile lengthening
tunica albuginea remodeling
vacuum device
Journal
Asian journal of andrology
ISSN: 1745-7262
Titre abrégé: Asian J Androl
Pays: China
ID NLM: 100942132
Informations de publication
Date de publication:
Historique:
pubmed:
19
11
2019
medline:
4
8
2021
entrez:
19
11
2019
Statut:
ppublish
Résumé
This study aimed to explore whether and how anti-lysyl oxidase (anti-LOX) combined with a vacuum device (VD) could promote penile lengthening and to evaluate the effect on erectile function. This study was performed on four groups of adult rats: control, anti-LOX, VD (negative pressure value of -300 mmHg), and anti-LOX + VD. Penile length was measured by a modified VD method and verified on exposed length data. Intracavernous pressure (ICP) and maximum ICP/mean arterial pressure (MAP) ratio were recorded to assess erectile function. For corpus cavernosum, LOX activity and concentrations of pyridinoline, desmosine, hydroxyproline, and elastin were analyzed; transmission electron microscope and Hart's elastin staining were performed to monitor microstructural changes. Anti-LOX and VD significantly lengthened the penis by 10.8% (3.75 mm) and 8.2% (2.48 mm) compared with the control group, respectively, while anti-LOX + VD achieved the longest penile size (40.58 ± 0.40 mm) which was 17.4% longer than the control group (34.58 ± 0.54 mm). After 1-week washout, no penile retraction was observed. Meanwhile, exposed penile length data confirmed that the penis in the anti-LOX + VD group was also significantly longer. Anti-LOX inhibited LOX activity to reduce pyridinoline level, which led the penile tunica albuginea remodeling. However, it had no effect on hydroxyproline, desmosine, and elastin levels. Moreover, anti-LOX had no impact on erectile function, which was determined by ICP and ICP/MAP ratio. These results suggest that anti-LOX elongates the penis by reducing pyridinoline, which induces tunica albuginea remodeling. This lengthening effect was more obvious when combined with a VD. All procedures had no impact on erectile function.
Identifiants
pubmed: 31736474
pii: 271074
doi: 10.4103/aja.aja_120_19
pmc: PMC7523611
doi:
Substances chimiques
Amino Acids
0
Enzyme Inhibitors
0
Desmosine
11003-57-9
beta-aminopropionitrile fumarate
1119-28-4
Aminopropionitrile
151-18-8
pyridinoline
63800-01-1
Collagen
9007-34-5
Elastin
9007-58-3
Protein-Lysine 6-Oxidase
EC 1.4.3.13
Hydroxyproline
RMB44WO89X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
485-492Déclaration de conflit d'intérêts
None
Références
J Cell Mol Med. 2018 Mar;22(3):2018-2022
pubmed: 29278308
J Sex Med. 2009 Dec;6(12):3247-53
pubmed: 19758281
J Sex Med. 2011 Jul;8(7):2112-7
pubmed: 21492409
Circulation. 2002 Nov 5;106(19):2503-9
pubmed: 12417550
J Sex Med. 2013 Jan;10(1):294-303
pubmed: 22512935
FASEB J. 2014 Jun;28(6):2725-35
pubmed: 24614760
BJU Int. 2009 Mar;103(6):793-7
pubmed: 18990153
BJU Int. 1999 Dec;84(9):1093-4
pubmed: 10571642
J Mol Histol. 2004 Nov;35(8-9):845-55
pubmed: 15609098
J Pediatr Endocrinol Metab. 2016 Feb;29(2):173-7
pubmed: 26352087
Cardiovasc Res. 1981 Jul;15(7):373-81
pubmed: 7307020
Eur Urol. 2006 Apr;49(4):609-11
pubmed: 16439051
J Sex Med. 2008 Jun;5(6):1468-73
pubmed: 18373527
J Pathol. 2015 Jul;236(3):373-83
pubmed: 25788370
Br J Urol. 1997 Jan;79(1):47-53
pubmed: 9043496
Am J Physiol Heart Circ Physiol. 2005 Nov;289(5):H2228-33
pubmed: 15951346
J Urol. 1999 Apr;161(4):1141-4
pubmed: 10081856
J Sex Med. 2011 Nov;8(11):3188-92
pubmed: 20102448
Toxicol Appl Pharmacol. 2010 Apr 15;244(2):156-61
pubmed: 20045017
J Sex Marital Ther. 2010;36(2):118-23
pubmed: 20169492
Nat Rev Urol. 2012 Sep;9(9):499-507
pubmed: 22890302
Am J Physiol Heart Circ Physiol. 2012 Oct 15;303(8):H1067-75
pubmed: 22904155
Atherosclerosis. 1998 Sep;140(1):135-45
pubmed: 9733224
J Urol. 1995 Aug;154(2 Pt 2):825-9
pubmed: 7609189
Circulation. 2012 Dec 18;126(25):3070-80
pubmed: 23136157
J Hand Surg Br. 1998 Jun;23(3):297-302
pubmed: 9665512
J Steroid Biochem Mol Biol. 1996 Mar;57(5-6):301-13
pubmed: 8639466
J Biol Chem. 2015 Jun 26;290(26):16440-50
pubmed: 25979340
J Androl. 2012 Jul-Aug;33(4):651-9
pubmed: 22016353
Arch Pediatr Adolesc Med. 2010 Dec;164(12):1152-7
pubmed: 21135345
Int J Androl. 2010 Feb;33(1):e144-52
pubmed: 19656234
Am J Physiol Heart Circ Physiol. 2010 Jul;299(1):H1-9
pubmed: 20472764
J Biomech. 2006;39(16):2983-90
pubmed: 16386746
Br J Urol. 1994 May;73(5):566-71
pubmed: 8012781
Curr Opin Urol. 2008 Nov;18(6):583-8
pubmed: 18832943
Asian J Androl. 2014 Nov-Dec;16(6):817-23
pubmed: 24994782
J Pediatr. 1999 May;134(5):579-83
pubmed: 10228293
BJU Int. 2011 Apr;107(8):1278-82
pubmed: 20868389
J Urol. 1994 Aug;152(2 Pt 2):734-9
pubmed: 8022007
Andrologia. 2018 Sep;50(7):e13051
pubmed: 29806152
Asian J Androl. 2004 Dec;6(4):365-8
pubmed: 15546031
Asian J Androl. 2019 Sep-Oct;21(5):516-521
pubmed: 30924453
J Hand Surg Br. 1994 Aug;19(4):522-7
pubmed: 7964107
Br J Urol. 1998 Nov;82(5):673-81
pubmed: 9839582
Sci Rep. 2017 Nov 2;7(1):14949
pubmed: 29097758
J Sex Med. 2017 Oct;14(10):1270-1276
pubmed: 28923308
Toxicol Appl Pharmacol. 2009 Sep 15;239(3):258-67
pubmed: 19524603
Eur Urol. 2010 Nov;58(5):773-80
pubmed: 20674151